Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1,060.80 -0.06 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1,060.80 -0.06 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Zacks News
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.
Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia (NTLA) Focuses on Developing Gene-Editing Therapies
by Zacks Equity Research
Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.
Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance
by Zacks Equity Research
Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.
Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale
by Zacks Equity Research
Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.
Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation
by Zacks Equity Research
The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.
J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off
by Zacks Equity Research
J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.
Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies
by Zacks Equity Research
Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery
by Zacks Equity Research
Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
by Zacks Equity Research
Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
by Zacks Equity Research
Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.
Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?
by Zacks Equity Research
Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.
Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies
by Zacks Equity Research
Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.
FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE
by Zacks Equity Research
If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.
The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management
by Zacks Equity Research
Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.
Top Stock Reports for Amazon.com, Boeing, Regeneron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).
Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.